Blog

Dec 15, 2021, 12:30 AM
AcuraStem (acurastem.com), a patient-based drug discovery platform company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced the results of extensive preclinical studies on its lead program, AS-202, for ALS patients. The data were presented at the Motor Neuron Disease Association 32nd International Symposium on ALS/MND on December 9, by AcuraStem’s Head of Research, Wen-Hsuan Chang, Ph.D.
Dec 6, 2021, 5:01 PM
AcuraStem will present posters at the 32nd International Symposium on ALS/MND.
Jun 28, 2021, 11:32 AM
The CMT Research Foundation today announced it has partnered with AcuraStem, a patient-based drug discovery platform company, and Dr. Alessandra Bolino, to test a new drug to fight  CMT4B1. Dr. Alessandra Bolino, who will lead the research and testing, is a renowned expert in CMT and head of the Human Inherited Neuropathies Unit at the prestigious research hospital Ospedale San Raffaele in Milan. 
May 25, 2021, 7:04 PM
AcuraStem has received an Amyotrophic Lateral Sclerosis Research Pro-gram (ALSRP) Therapeutic Development Award from the Department of Defense, Congressionally Directed Medical Research Programs (CDMRP) totaling $1 million.
Sep 21, 2020, 7:52 AM
“We are excited to add our collaborator Dr. Robert Bowser to our advisory board. Bob is a worldwide leader in ALS biomarker development. His expertise will be critical as we look to validate key, CNS-specific, mechanistic biomarkers for our PIKFYVE programs,” said Sam Alworth, co-founder and chief executive officer of AcuraStem.
Nov 7, 2019, 12:08 AM
AcuraStem was honored to once again partner with Team Nanci and the ALS Association Golden West Chapter in the fight against ALS as a sponsor of the 17th Annual Los Angeles County Walk to Defeat ALS® on Sunday, November 3, at Exposition Park in Los Angeles.
Oct 22, 2019, 6:47 PM
AcuraStem announced today that the company has triggered Phase II funding worth $3 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).
Jan 15, 2019, 11:20 AM
MDA has awarded an MVP grant totaling $300,000 over two years to AcuraStem to support preclinical development of a novel small molecule therapeutic for ALS.
Dec 20, 2018, 10:38 AM
CMT Research Foundation announced today it has entered into a collaborative research partnership with AcuraStem to test thousands of compounds aimed at producing effective treatments for Charcot-Marie-Tooth disease.
Nov 2, 2018, 11:59 PM
AcuraStem will join in the fight against ALS as a sponsor of the 16th Annual Los Angeles County Walk to Defeat ALS® on Sunday, November 4, at Exposition Park in Los Angeles. The team will walk with “Team Nanci” and be on hand at the AcuraStem booth to talk to patients and families affected by Amyotrophic Lateral Sclerosis (ALS) about its mission and research underway.